CR20230410A - Derivados novedosos de pirimidin-2-il-sulfonamida - Google Patents

Derivados novedosos de pirimidin-2-il-sulfonamida

Info

Publication number
CR20230410A
CR20230410A CR20230410A CR20230410A CR20230410A CR 20230410 A CR20230410 A CR 20230410A CR 20230410 A CR20230410 A CR 20230410A CR 20230410 A CR20230410 A CR 20230410A CR 20230410 A CR20230410 A CR 20230410A
Authority
CR
Costa Rica
Prior art keywords
sup
sulfonamide derivatives
sub
novel
pyrimidin
Prior art date
Application number
CR20230410A
Other languages
English (en)
Inventor
Guido Galley
Luca Gobbi
Dmitry Mazunin
Wolfgang Guba
Emmanuel Pinard
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230410A publication Critical patent/CR20230410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos que tienen la fórmula general I <img alt="" src="data:image/png;base64,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 (***)
CR20230410A 2021-02-26 2022-02-24 Derivados novedosos de pirimidin-2-il-sulfonamida CR20230410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21159452 2021-02-26
PCT/EP2022/054586 WO2022180136A1 (en) 2021-02-26 2022-02-24 Novel pyrimidin-2-yl sulfonamide derivatives

Publications (1)

Publication Number Publication Date
CR20230410A true CR20230410A (es) 2023-09-25

Family

ID=74797733

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230410A CR20230410A (es) 2021-02-26 2022-02-24 Derivados novedosos de pirimidin-2-il-sulfonamida

Country Status (17)

Country Link
US (1) US20240025883A1 (es)
EP (1) EP4298092A1 (es)
JP (1) JP2024507176A (es)
KR (1) KR20230152006A (es)
CN (1) CN116829550A (es)
AR (1) AR124973A1 (es)
AU (1) AU2022227183A1 (es)
CA (1) CA3203282A1 (es)
CL (1) CL2023002429A1 (es)
CO (1) CO2023010212A2 (es)
CR (1) CR20230410A (es)
IL (1) IL304450A (es)
MX (1) MX2023009045A (es)
PE (1) PE20240125A1 (es)
TW (1) TW202245749A (es)
WO (1) WO2022180136A1 (es)
ZA (1) ZA202305344B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023128A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives
WO2024023129A1 (en) * 2022-07-28 2024-02-01 F. Hoffmann-La Roche Ag Novel 7-substituted indole sulfonamide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
EP3584244A1 (en) * 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides

Also Published As

Publication number Publication date
AU2022227183A1 (en) 2023-06-22
CO2023010212A2 (es) 2023-09-08
AR124973A1 (es) 2023-05-24
IL304450A (en) 2023-09-01
MX2023009045A (es) 2023-08-10
CL2023002429A1 (es) 2024-01-12
US20240025883A1 (en) 2024-01-25
CA3203282A1 (en) 2022-09-01
KR20230152006A (ko) 2023-11-02
WO2022180136A1 (en) 2022-09-01
PE20240125A1 (es) 2024-01-22
CN116829550A (zh) 2023-09-29
JP2024507176A (ja) 2024-02-16
TW202245749A (zh) 2022-12-01
EP4298092A1 (en) 2024-01-03
ZA202305344B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
MX2023002224A (es) Compuestos heterociclicos.
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
ATE433447T1 (de) Pyrimiidinverbindungen
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
CR20220116A (es) Compuestos heterocíclicos
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20230496A (es) Compuestos heterocíclicos
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200800974A (en) Glucuronate salt of a piperazine compound
MX2022007369A (es) Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
CR20220004A (es) Nuevos compuestos heterocíclicos
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
CR20230529A (es) Inhibidores de nlrp3
MX2021003427A (es) Nuevos oxadiazoles.
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
CR20220478A (es) Derivados de benzodiazepinas como pam de gaba a gamma 1
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
MX2009008028A (es) Agentes antiparasitarios.
ATE505462T1 (de) Neue biologischaktive molekü le